SCHEMBL2803749

SCHEMBL2803749

COc1ccccc1-c1n[nH]c2ncc3c(c12)CCN(C(=O)Nc1ccccc1)C3

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.53
NPC1 O15118 4/20 0.45
RAB9A P51151 4/20 0.45
TP53 P04637 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
RYR2 Q92736 1/20 0.42
LIMK1 P53667 2/20 0.42
LIMK2 P53671 2/20 0.42
CCNT1 O60563 1/20 0.42
CDK9 P50750 1/20 0.42
TRPV1 Q8NER1 3/20 0.41
PDE10A Q9Y233 2/20 0.41
ROCK2 O75116 1/20 0.41
NAMPT P43490 1/20 0.41
PDGFRB P09619 1/20 0.41
SIRT5 Q9NXA8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2488267 0.89 NPC1 (0.47) THRBNPC1RAB9ATP53SMN1; SMN2
SCHEMBL2512524 0.86 NPC1 (0.51) THRBNPC1RAB9ATP53SMN1; SMN2
SCHEMBL2805115 0.84 NPC1 (0.53) THRBNPC1RAB9ARYR2LIMK1
SCHEMBL2809284 0.82 NPC1 (0.46) THRBNPC1RAB9ATP53SMN1; SMN2
SCHEMBL2809552 0.81 RAB9A (0.44) THRBNPC1RAB9ATP53SMN1; SMN2
SCHEMBL2803761 0.81 RAB9A (0.52) THRBNPC1RAB9ATP53SMN1; SMN2
SCHEMBL12316013 0.80 NAMPT (0.52) THRBNPC1RAB9ATP53SMN1; SMN2
SCHEMBL2805950 0.80 NAMPT (0.47) THRBNPC1RAB9ATP53SMN1; SMN2
Hydrochloric Acid SCHEMBL2513170 0.80 NAMPT (0.52) THRBNPC1RAB9ATP53SMN1; SMN2
SCHEMBL2804192 0.79 ROCK2 (0.43) THRBNPC1RAB9ATP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 THRB 4459/4885NPC1 205/4885RAB9A 1240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.